News | November 13, 2008

Heart's Surplus Energy May Help Power Pacemakers, Defibrillators

November 14, 2008 - Surplus energy generated by the heart may one day help power pacemakers and defibrillators implanted in cardiac patients, according to research presented this week at the American Heart Association's Scientific Sessions 2008 in New Orleans.

In a trailblazing experiment, a microgenerator powered by heartbeats produced almost 17 percent of the electricity needed to run a pacemaker.

"This was a proof-of-concept study, and we proved the concept," said Paul Roberts, M.D., first author of the study and a consultant electrophysiologist at Southampton University Hospital in the U.K. "Harvesting surplus energy might be a major transition in implantable pacemakers and defibrillators because engineers will have more energy to work with."

In their study, researchers found at a heart rate of 80 beats per minute (bpm), the device yielded an average harvested energy of 4.3 microjoules per cardiac cycle. Increasing changes in the heart rate produced corresponding increases in energy. At 104 to 128 bpm, the harvested energy level increased 140 percent. Decreases occurred when the researchers slowed the heartbeat or lowered blood pressure. Researchers said implantation and surplus energy harvesting caused no significant injury to the lining of the heart's chambers.

"What this might mean is that in the next era of pacemakers, you'd get devices that lasted significantly longer and we could add more functions to help monitor the heart," Roberts said. "It's possible they could be efficient enough to allow complete and indefinite powering of pacemakers."

Since their introduction into clinical medicine, implantable pacemakers and defibrillators have saved lives and become more sophisticated. However, adding new monitoring capabilities to the devices has led designers to a critical point.

"The small devices now are really very good, but power consumption must increase if we want to take them to the next level," Dr. Roberts said. "Battery technology has plateaued and the only way we are going to increase power is to increase size."

This, in turn, would increase the units' weight, making them more uncomfortable and less cosmetically acceptable to patients because the devices are implanted under the skin.

The innovative generator, called the self-energizing implantable medical microsystem (SIMM), helps the heart produce more than enough energy with each beat to pump blood. The SIMM uses two compressible bladders and a microgenerator mounted on the lead of a pacemaker or defibrillator, the wire that connects the device to the heart.

The lead is attached to the end of the right ventricle, and the bladders relay the energy from the pressure of each heartbeat to the microgenerator, which transforms it into electricity for use by the battery.

A consortium of companies including InVivo Technology, Perpetuum and Zarlink Semiconductor developed and tested the SIMM microgenerator with U.K. government funds. Researchers used an in-vivo porcine model to evaluate the study. The researchers are now working to improve the materials used in the SIMM microgenerator.

"With different materials, we�re seeing even greater energy harvesting," Roberts said. "While at the moment we see about 20 percent harvesting, we're anticipating that will be significantly more in the next iteration of the device."

Dr. Roberts holds ownership interests in InVivo Technology and serves on its Scientific Advisory Board.

The United Kingdom Technology Strategy Board funded the SIMM project.

For more information: www.americanheart.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init